NCT02556099View on ClinicalTrials.gov

EXTEND EXpanding Treatment for Existing Neurological Disease

PHASE2CompletedINTERVENTIONAL
Enrollment

43

Participants

Timeline

Start Date

August 31, 2014

Primary Completion Date

January 16, 2023

Study Completion Date

January 16, 2023

Conditions
Sickle Cell Anemia
Interventions
DRUG

Hydroxyurea

drug to be administered

Trial Locations (1)

Unknown

Sickle Cell Unit, Kingston

All Listed Sponsors
collaborator

Caribbean Institute for Health Research (CAIHR)

UNKNOWN

lead

Children's Hospital Medical Center, Cincinnati

OTHER

NCT02556099 - EXTEND EXpanding Treatment for Existing Neurological Disease | Biotech Hunter | Biotech Hunter